<?xml version="1.0" encoding="UTF-8"?>
<document id="30429449">
	<sentence id="s1" text="BACKGROUND RET rearrangements have been reported in 30% of papillary thyroid carcinomas and 1-2% of non-small cell lung cancer (NSCLC).">
		<entity id="s1.e1" charOffset="11-14"
			type="GENE" text="RET" ontology_id="5979"/>
		<entity id="s1.e2" charOffset="59-87"
			type="HP" text="papillary thyroid carcinomas" ontology_id="HP_0002895"/>
		<entity id="s1.e3" charOffset="120-126"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
		<pair id="s1.p2" e1="s1.e1"
		    e2="s1.e3" pgr="true"/>
	</sentence>
	<sentence id="s2" text="In these tumors, RET gene fusion product provides a constitutively active tyrosine kinase (TKR), leading to uncontrolled cellular proliferation, differentiation, and migration.">
		<entity id="s2.e1" charOffset="9-15"
			type="HP" text="tumors" ontology_id="HP_0002664"/>
		<entity id="s2.e2" charOffset="17-20"
			type="GENE" text="RET" ontology_id="5979"/>
		<entity id="s2.e3" charOffset="91-94"
			type="GENE" text="TKR" ontology_id="8277"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="true"/>
		<pair id="s2.p2" e1="s2.e1"
		    e2="s2.e3" pgr="false"/>
	</sentence>
	<sentence id="s3" text="In this investigation we assessed the positivity rate of RET gene rearrangement in primary and metastatic non-small cell lung cancer and explored their relationships.">
		<entity id="s3.e1" charOffset="57-60"
			type="GENE" text="RET" ontology_id="5979"/>
		<entity id="s3.e2" charOffset="126-132"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="true"/>
	</sentence>
	<sentence id="s4" text="The RET rearrangement uniformity in metastatic lymph nodes and tumor specimens were contrasted and the relationships between RET rearrangement and patients' clinical features were investigated.">
		<entity id="s4.e1" charOffset="4-7"
			type="GENE" text="RET" ontology_id="5979"/>
		<entity id="s4.e2" charOffset="63-68"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="true"/>
	</sentence>
	<sentence id="s5" text="RESULTS For those 384 cases, 7 (1.82%) cases had tumors with identified RET rearrangement.">
		<entity id="s5.e1" charOffset="49-55"
			type="HP" text="tumors" ontology_id="HP_0002664"/>
		<entity id="s5.e2" charOffset="72-75"
			type="GENE" text="RET" ontology_id="5979"/>
		<pair id="s5.p1" e1="s5.e1"
		    e2="s5.e2" pgr="true"/>
	</sentence>
	<sentence id="s6" text="Among the 246 paired cases, 3 (1.22%) cases of primary tumor had identified RET rearrangement and 2 (0.81%) cases of metastases had identified RET rearrangement.">
		<entity id="s6.e1" charOffset="55-60"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s6.e2" charOffset="76-79"
			type="GENE" text="RET" ontology_id="5979"/>
		<pair id="s6.p1" e1="s6.e1"
		    e2="s6.e2" pgr="true"/>
	</sentence>
	<sentence id="s7" text="CONCLUSIONS The results of this research indicate that the metastases of non-small cell lung cancer can predict RET rearrangement of the primary tumor tissue in the majority of cases.">
		<entity id="s7.e1" charOffset="93-99"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s7.e2" charOffset="112-115"
			type="GENE" text="RET" ontology_id="5979"/>
		<entity id="s7.e3" charOffset="145-150"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s7.p1" e1="s7.e1"
		    e2="s7.e2" pgr="true"/>
		<pair id="s7.p2" e1="s7.e2"
		    e2="s7.e3" pgr="true"/>
	</sentence>
	<sentence id="s8" text="Testing for RET rearrangement in metastases can be used as an alternative to testing of primary tumor tissue if it is inaccessible">
		<entity id="s8.e1" charOffset="12-15"
			type="GENE" text="RET" ontology_id="5979"/>
		<entity id="s8.e2" charOffset="96-101"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s8.p1" e1="s8.e1"
		    e2="s8.e2" pgr="true"/>
	</sentence>
</document>
